← Back to Clinical Trials
Recruiting NCT05912569

NCT05912569 Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05912569
Status Recruiting
Phase
Sponsor Seoul National University Hospital
Condition DCIS
Study Type INTERVENTIONAL
Enrollment 84 participants
Start Date 2023-06-13
Primary Completion 2025-04-28

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Delay sentinel node biopsy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 84 participants in total. It began in 2023-06-13 with a primary completion date of 2025-04-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In the case of a patient undergoing total mastectomy for intraductal carcinoma (DCIS), the sentinel lymph node is not excised during the primary surgery but only marked for identification. If the final histological examination confirms invasive cancer, delayed surgery is performed to remove the sentinel lymph node that was marked during the initial surgery. primary endpoint : The success rate of identifying the sentinel lymph node that was marked during the primary surgery in cases where the final histological examination confirms invasive cancer is evaluated. addendum) The previously documented Breast-Conserving Surgery has been corrected to reflect the accurate procedure of Total Mastectomy.

Eligibility Criteria

Inclusion Criteria: * Patients aged 20 to 75 years old. * Patients diagnosed with DCIS through histological examination. * Patients undergoing mastectomy Exclusion Criteria: * In cases where the histopathological findings of the tissue examination indicate suspicious invasive lesions. * In cases where imaging tests or physical examinations suggest possible lymph node metastasis. * In patients who have previously undergone axillary lymph node surgery on the same side as the current procedure. * Pregnant patients.

Frequently Asked Questions

Who can join the NCT05912569 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 75 Years, studying DCIS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05912569 currently recruiting?

Yes, NCT05912569 is actively recruiting participants. Visit ClinicalTrials.gov or contact Seoul National University Hospital to inquire about joining.

Where is the NCT05912569 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT05912569 clinical trial?

NCT05912569 is sponsored by Seoul National University Hospital. The trial plans to enroll 84 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology